Partner With Us NRI

Nureca Ltd share Price Today

Company details

6M Return -33.88%
1Y Return -22.83%
Mkt Cap.(Cr) 275.30
Volume 14,834
Div Yield 0.00%
OI Chg %
Volume 14,834

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Supplies firm Nureca announced Q1FY23 Result :

  • GMV of Q1’FY23 stood at Rs. 338 mn as compared to Rs. 1627 Mn in Q1’FY22, decrease of 79%
  • Operating Revenue was Rs. 255 mn in Q1’FY23 as compared to Rs. 1,195 in Q1’FY22, decrease of 79%
  • Overall, demand has seen a dip in Q1’FY23 as compared to the same quarter last year, which had seen a huge surge in demand due to Covid-19
  • Our Gross margins in Q1’FY23 were impacted due to lower demand, inflation in input cost, currency fluctuation as well as inflationary pressure in other non-core costs such as packaging, transport, etc.
  • Our employee cost has increased as compared to the same quarter last year due to aggressive talent acquisition across the business functions and verticals majorly for app development and expansion of Offline distribution network.
  • Other expenses are lower in Q1’FY23 by 52%, in line with the top line.
  • Overall, EBITDA was Rs. (46) mn in Q1’FY23, lower by 109% and PAT stood at Rs. (41) mn, lower by 111%


Result PDF

View Other Company Results

Nureca Ltd shares SWOT Analysis

Strengths (5)

  • Company with Low Debt
  • Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
  • Company with Zero Promoter Pledge

Weakness (7)

  • Red Flag: High Interest Payments Compared to Earnings
  • Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
  • Declining Revenue every quarter for the past 2 quarters

Opportunity (1)

  • Stock with Low PE (PE < = 10)

Threats (1)

  • Companies with growing costs YoY for long term projects

Resistance and support

R1 277.9
R2 280.6
R3 282.0


S1 273.8
S2 272.4
S3 269.7
Delivery and volume
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-12-26 453.24 182264 NSE
QE SECURITIES LLP Bulk Purchase 2023-12-26 452.64 68304 NSE
AAKRAYA RESEARCH LLP Bulk Purchase 2023-12-26 452.69 66791 NSE
Name Category Shares


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Nureca Ltd Stocks COMPARISON

Financials( in Cr) Nureca Ltd Zomato Ltd Info Edge (India) Ltd FSN E-Commerce Ventures Ltd One 97 Communications Ltd
Price 275.30 222.47 6,861.50 180.29 465.95
% Change -0.69 5.25 1.18 2.86 -0.26
Mcap Cr 275.30 196,213.73 88,776.83 51,490.57 29,607.12
Revenue TTM Cr 91.93 7,079.40 2,345.69 5,143.80 7,990.30
Net Profit TTM Cr -1.79 -971.00 -70.46 24.82 -1,776.50
PE TTM 0.00 0.00 136.73 0.00 0.00
1 Year Return -22.83 197.42 58.40 29.29 -43.42
ROCE -4.00 0.00 2.92 5.09 0.00
ROE -3.14 0.00 -1.64 1.76 0.00

Equity Capital: 193.11 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,015.43 44,980.72
LAST 3M 106,765.53 41,611.09
LAST 6M 195,525.59 13,104.33
LAST 12M 310,530.02 79,314.43

Nureca Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • The Company was formerly incorporated as Nureca Private Limited in India on 02 November 2016 under the provisions of Companies Act, 2013. The Company got converted from Private Limited Company to a Public Limited Company with effect from 08 July 2020 and the name of Company was changed to Nureca Limited. The Company is engaged in the business of home healthcare and wellness products. The Company is a leading healthcare and wellness company with a product range of over 150 SKUs across different categories. The flagship brands such as Dr. Trust continue to enjoy high credibility and a loyal customer base. The products comply with USFDA, European CE, ROHS and ISO certifications, which reinforce customer`s belief in their products. At present, the Company holds more than 100 design products. Nureca is a digital first, B2C company. The Company sell products through implementation of various digital online platform channels like Flipkart, Amazon and website http://drtrust.in/. Dr. Trust is a pioneer in global healthcare and wellness brand with patented technologies and innovative solutions, helping users monitor chronic ailments. The Company is committed to creating products that support diagnosis, treatment and prevention of illness through monitoring and analysis of health data. Nureca`s products are manufactured to be safe, accurate, long-lasting, and compliant with national and international regulations. The Company`s growing range of connected devices is well entrenched in IoT and easy to sync with smart devices, while health app provides secure consolidation of data. The Company is focused on leveraging its innovation, research, and data science capabilities to help and empower more people living with chronic and lifestyle diseases to live healthier and happier lives. The Company envisaged digital ecosystem and principles aims to provide integrated solutions aiding customers to maintain a suitable fitness regime, have clear understanding of and control over existing diseases with easier health monitoring at home and optimum nutrition through quality nutraceuticals. In 2017, the Company commenced business operations and launched `Dr. Trust` brand through digital healthcare channel. In 2018, the Company widened product basket with launching of brands in electric massages and mother & child care categories like Dr. Physio and Trumom. The Company started three flex centers in Punjab, Karnataka and Uttar Pradesh. In 2019, the Company took the initiative for commencing business with WS retail. It increased the aggregate number of SKUs to 150. The Company added three flex centers in Tricity Chandigarh, Telangana and Maharashtra. The Company`s key products secured a warehouse drug license. In 2020, Company expanded presence through different channels and took initiative for starting business with 1mg, Pharmeasy, Paytm, and Croma retail stores. The Company had taken the effect of demerger as per the Scheme of Arrangement among Nectar Biopharma Private Limited (demerged company) and Nureca Private Limited (resulting company) and their respective shareholders and creditors under Section 230 to 232 and other applicable provisions of the Companies Act 2013, which has been sanctioned by the Honorable National Company Law Tribunal (NCLT), Mumbai vide its Order dated 29 April 2020. The Scheme had become effective on 23 May 2020 (Effective date) on filing of certified copy of the Order with the Registrar of Companies. The Appointed Date from which the Scheme was operative was 1 April 2019. Pursuant to the Scheme of Demerger, certain portion of business activities of the demerged company was transferred by Nectar Biopharma Private Limited from the Appointed date of 1 April 2019. In FY 2021, the Company received prestigious `Economic Times Best Healthcare Brands Award 2021`.

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543264
Book Closure Date (Month) : Jul
BSE Group : B

FAQ’s on Nureca Ltd Shares

You can buy Nureca Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Nureca Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 12, 2024 03:48 PM the closing price of Nureca Ltd was Rs.275.30.

The latest PE ratio of Nureca Ltd as of Jul 12, 2024 03:48 PM is 0.00

The latest PB ratio of Nureca Ltd as of Jul 12, 2024 03:48 PM is 0.70

The 52-week high of Nureca Ltd share price is Rs. 468.80 while the 52-week low is Rs. 240.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 12, 2024 03:48 PM, the market cap of Nureca Ltd stood at Rs. 275.30 Cr.

Download App

Download Our App

Play Store App Store
market app